Pharma join together to achieve new standards in digital and patient innovation for clinical transformation

Reuters Events 17 - 19 May 2022, Virtual.
On May 17th , 500+ of pharma's clinical innovation will come together for the home of clinical collaboration, Reuters Events: Pharma Clinical 2022, to set new standards in digital and patient innovation for clinical transformation.

The catalyst for this has been the accelerated technological adoption in clinical trials, but a general feeling still that enough isn't being done for patients, failing to develop co-created, data-driven, standardised and accountable trial design.

Senior leaders from Sanofi, Pfizer, Bayer, FDA, AstraZeneca, Johnson & Johnson, Bristol Myers Squibb, Roche, Novartis and more are collaborating on May 17 th , with one mission in mind: it's time to develop a better system. "We must establish new industry-wide benchmarks, leverage digital technology, and ensure permanent cultural change toward patient- centric trials. If we don't act immediately, we risk losing patient trust." Said Usmaan Khan, Global Project Director and leader for Reuters Events: Pharma Clinical 2022.

The community is growing every day so don't miss out on the opportunity to be part of this movement- this event is free for pharma and biotech executives, patient advocates and patient associations! Secure your pass today here.

About Reuters Events: Pharma Clinical 2022, May 17-19th

Reuters Events: Pharma Clinical is proud to host a one-of-a-kind lineup, with more than 40 world-class and professional speakers. Among the speakers are:
  • Jijo James, CMO, Medical Devises, Johnson & Johnson
  • Lionel Bascles, SVP, Global Head of Clinical Sciences & Operations, Sanofi
  • Craig Lipset, Advisor and founder, Clinical Innovations Partners
  • Loredana Regep, VP Medical and Regulatory Affairs, Roche
  • Najat Khan, Chief Data Science Officer, Global Head, Janssen R&D Strategy and Operations, Johnson & Johnson
  • Dietmar Berger, CMO, Global Head of Development, Sanofi
  • Tracy Vanderslice, VP & Head, Pharma Global Clinical Operations, GSK
  • Venkat Sethuraman, SVP Global Biometrics and Data Science, Bristol-Myers Squibb

Click here to discover the full speaker line-up now!

Why should you attend?

On last year's event, Mo Ali, VP Digital Analytics and Performance said: "Clinical 2021 allows for open discussions around how we can do this, by sharing experiences and learnings, we expand on the art of the possible from what once several years ago may have been viewed as impossible"

Clinical 2022 builds on this with our insight-driven agenda co-created with industry leaders to guarantee you acquire practical knowledge that will help you succeed. With 40+ speakers, you'll access critical sessions related to:

  • Benchmark industry-wide clinical innovation: Align standards across stakeholders, establish benchmarks, maintain accountability, and set industry-wide goals to improve patient experience and trial performance
  • Co-creation or no creation: Create shared missions, education programmes, and centre digital advances around patients to create trial designs that work in the real world
  • Optimise your digital and data strategies for novel endpoints: Develop trial flexibility, design efficiency, and unique RWE endpoints through standardised and tested innovations
  • Data collaboration: Ensure smooth interoperable data transmissions across the company's digital innovation and health networks for streamlined trials
  • Evolve decentralised trials: Allow decentralised trials to thrive by providing ongoing trial breakthroughs that are backed by regulators and prioritise the patient.

Interested in sponsoring or speaking at Clinical 2022? Fill out the form here.

For further information and to register, please visit Pharma Clinical 2022

About Reuters Events

Our mission is to make pharma more open and valued.

More open so that the strongest ideas and insights are brought to the fore in a transparent, trustworthy manner. More valued by having an authentic approach to building products and services that matter to patients.

To do this, Reuters Events provides a hub for senior-level pharma executives, patient groups and other health stakeholders to exchange ideas and observe shifting trends and practices. We provide commentary, events, reports, and other expert-driven content. One of our biggest strengths is to be able to gather advice, examples and understanding on the best industry work, articulate this across multiple channels, and create a mass movement to help us all improve. This is how we will serve patients better.

We actively respond to the aims and interests of our audience, so please get in touch if you think we can do more.

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...